现金流告急！又一家Biotech裁员75%

Core Viewpoint - Heidelberg Pharma plans to lay off 75% of its workforce due to financial strain following the FDA's rejection of Telix Pharmaceuticals' imaging agent, which was expected to provide significant milestone payments and royalties [1][2]. Group 1: Financial Situation - Heidelberg Pharma's financial situation has become critical, with only €33 million (approximately $39 million) available as of mid-2025, which is expected to last until the first quarter of 2026 [1][2]. - The company had anticipated receiving $70 million upon FDA approval of TLX250-CDx, which has now been jeopardized by the FDA's decision [1][3]. Group 2: Workforce Reduction - The company plans to reduce its employee count from 122 to approximately 30 by mid-2026 as a measure to extend its financial runway [2]. - This workforce reduction is part of a broader strategy to manage costs and maintain basic operations amid funding challenges [2]. Group 3: Research and Development Strategy - Heidelberg Pharma will continue the development of its lead antibody-drug conjugate, HDP-101, which is currently in a Phase 1/2a clinical trial for multiple myeloma [2][4]. - The development of a second antibody-drug conjugate, HDP-102, has been suspended, while the company plans to submit a clinical trial application for a third candidate, HDP-103 [2][3]. - The company is also halting early research activities and seeking opportunities to out-license its preclinical projects targeting gastrointestinal tumors [2][3]. Group 4: Product Pipeline and Market Position - HDP-101 is a novel anti-BCMA antibody-drug conjugate that has received orphan drug designation from the FDA for treating multiple myeloma [4]. - The unique mechanism of HDP-101 may provide advantages in treating hematological diseases with low proliferation rates compared to other ADCs like GSK's Blenrep [4].